JP2016515546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515546A5 JP2016515546A5 JP2016504349A JP2016504349A JP2016515546A5 JP 2016515546 A5 JP2016515546 A5 JP 2016515546A5 JP 2016504349 A JP2016504349 A JP 2016504349A JP 2016504349 A JP2016504349 A JP 2016504349A JP 2016515546 A5 JP2016515546 A5 JP 2016515546A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- alkenyl
- alkynyl
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 31
- 125000003342 alkenyl group Chemical group 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 125000000304 alkynyl group Chemical group 0.000 claims description 20
- 150000001540 azides Chemical group 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 210000004881 tumor cell Anatomy 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 5
- 230000032823 cell division Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000004906 unfolded protein response Effects 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000037841 lung tumor Diseases 0.000 claims description 3
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 2
- -1 Acyl homoserine lactone Chemical compound 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 230000016914 response to endoplasmic reticulum stress Effects 0.000 claims 1
- 0 *CCCCCCCCCC1(CC(N[C@](CCO2)C2=O)=O)NN1 Chemical compound *CCCCCCCCCC1(CC(N[C@](CCO2)C2=O)=O)NN1 0.000 description 4
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 2
- OKMZKEXNWLVMQV-JTOQLSFASA-N CCCCCCCCCC1(CC(N[C@@H](CCO2)C2=O)=O)N(C)N1 Chemical compound CCCCCCCCCC1(CC(N[C@@H](CCO2)C2=O)=O)N(C)N1 OKMZKEXNWLVMQV-JTOQLSFASA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361803177P | 2013-03-19 | 2013-03-19 | |
| US61/803,177 | 2013-03-19 | ||
| PCT/US2014/031235 WO2014153415A2 (en) | 2013-03-19 | 2014-03-19 | Trail enhancers for the selective killing of cancer cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515546A JP2016515546A (ja) | 2016-05-30 |
| JP2016515546A5 true JP2016515546A5 (https=) | 2017-05-25 |
| JP6307149B2 JP6307149B2 (ja) | 2018-04-04 |
Family
ID=51581796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016504349A Expired - Fee Related JP6307149B2 (ja) | 2013-03-19 | 2014-03-19 | 癌細胞を選択的に死滅させるためのｔｒａｉｌエンハンサー |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9604950B2 (https=) |
| EP (1) | EP2976076B1 (https=) |
| JP (1) | JP6307149B2 (https=) |
| KR (2) | KR101819874B1 (https=) |
| CN (1) | CN105228618A (https=) |
| AU (1) | AU2014236003A1 (https=) |
| CA (1) | CA2907668C (https=) |
| WO (1) | WO2014153415A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2976076B1 (en) | 2013-03-19 | 2020-03-04 | The Scripps Research Institute | Trail enhancers for the selective killing of cancer cells |
| US10195177B2 (en) | 2015-10-01 | 2019-02-05 | The University Of Toledo | Use of acyl-homoserine lactone derivatives as anti-thrombotic agents |
| CN105504000B (zh) * | 2016-01-21 | 2019-06-07 | 福建农林大学 | 一种筛选n-酰基高丝氨酸内酯类模拟物的方法 |
| US12329734B2 (en) | 2017-12-19 | 2025-06-17 | Axcess Global Sciences, Llc | Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow |
| US12533346B2 (en) | 2016-04-19 | 2026-01-27 | Axcess Global Sciences, Llc | Administration of berberine metabolites |
| US12599579B2 (en) | 2016-04-19 | 2026-04-14 | Axcess Global Sciences, Llc | Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids |
| US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
| US12109182B2 (en) | 2016-04-19 | 2024-10-08 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US12521378B2 (en) | 2016-04-19 | 2026-01-13 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans |
| US20230346721A1 (en) | 2018-04-18 | 2023-11-02 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies |
| US12496283B2 (en) | 2016-04-19 | 2025-12-16 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| EP3666908A1 (en) * | 2016-06-03 | 2020-06-17 | Institut national de recherche pour l'agriculture, l'alimentation et l'environnement | Diet controlled expression of a nucleic acid encoding a pro-apoptotic protein |
| US12171735B2 (en) | 2017-04-19 | 2024-12-24 | Axcess Global Sciences, Llc | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans |
| CN110935012A (zh) * | 2019-12-19 | 2020-03-31 | 东北师范大学 | 一种用于治疗肿瘤的药物组合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9924195D0 (en) * | 1999-10-13 | 1999-12-15 | Univ Nottingham | N-Acyl homoserine lactones for the treatment of cardiac tachyarrhythmias Ischaemic heart disease or congestive heart failure |
| GB0122914D0 (en) * | 2001-09-22 | 2001-11-14 | Univ Nottingham | Modulation of stat activity |
| JP2004231556A (ja) * | 2003-01-29 | 2004-08-19 | Nobuhiko Nomura | アポトーシス誘導剤 |
| WO2004075839A2 (en) * | 2003-02-21 | 2004-09-10 | Irm Llc | Methods and compositions for modulating apoptosis |
| US20070010477A1 (en) * | 2005-04-07 | 2007-01-11 | Dolnick Bruce J | Acyl homoserine lactones for inhibition of cell growth |
| WO2007007207A2 (en) * | 2005-04-13 | 2007-01-18 | Khairia Youssef | Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation |
| GB0610042D0 (en) * | 2006-05-22 | 2006-06-28 | Univ Nottingham | Substituted n-acyl homoserine lactones |
| EP2448930B1 (en) * | 2009-07-03 | 2017-02-15 | The National Institute for Biotechnology in the Negev Ltd. | N-((S)-2-Oxo-tetrahydro-furan-3-yl)-amide derivatives as inhibitors of the bacterial quorum sensing for treating plant or animal diseases and for preventing the formation of biofilms on medical devices |
| EP2976076B1 (en) | 2013-03-19 | 2020-03-04 | The Scripps Research Institute | Trail enhancers for the selective killing of cancer cells |
-
2014
- 2014-03-19 EP EP14770705.3A patent/EP2976076B1/en active Active
- 2014-03-19 KR KR1020177014484A patent/KR101819874B1/ko not_active Expired - Fee Related
- 2014-03-19 US US14/778,327 patent/US9604950B2/en not_active Expired - Fee Related
- 2014-03-19 KR KR1020157030159A patent/KR101743383B1/ko not_active Expired - Fee Related
- 2014-03-19 JP JP2016504349A patent/JP6307149B2/ja not_active Expired - Fee Related
- 2014-03-19 WO PCT/US2014/031235 patent/WO2014153415A2/en not_active Ceased
- 2014-03-19 CN CN201480028681.0A patent/CN105228618A/zh active Pending
- 2014-03-19 AU AU2014236003A patent/AU2014236003A1/en not_active Abandoned
- 2014-03-19 CA CA2907668A patent/CA2907668C/en active Active
-
2016
- 2016-12-22 US US15/389,073 patent/US9765061B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016515546A5 (https=) | ||
| Kindt et al. | Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets | |
| ECSP22018571A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| CY1118191T1 (el) | Αναλογα δεοξυνοζιριμυκινης και οι χρησεις τους ως αναστολεις γλυκοζυλοκεραμιδασης | |
| JP2013509429A5 (https=) | ||
| JP2015511609A5 (https=) | ||
| JP2015532296A5 (https=) | ||
| RU2018106483A (ru) | Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr | |
| JP2007508361A5 (https=) | ||
| RU2015149010A (ru) | Биологические маркеры, которые могут быть использованы в иммунотерапии рака | |
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| RU2022104034A (ru) | Фармацевтические композиции | |
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2015502371A5 (https=) | ||
| AR072611A1 (es) | Compuestos de 3-(fenoxifenilmetil)pirrolidina, un metodo para su preparacion, intermediario de sintesis y su proceso de obtencion, composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de 5-ht y ne. | |
| SE0402925D0 (sv) | Novel Compounds | |
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 | |
| JP2016515550A5 (https=) | ||
| ES2924728T3 (es) | Derivados de carbazol para el tratamiento de enfermedades fibróticas, así como de síntomas y afecciones relacionados con las mismas | |
| BR112017021669A2 (pt) | formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações | |
| JP2015522592A5 (https=) | ||
| MX378947B (es) | Composición farmacéutica estable para administración oral. | |
| JOP20240262A1 (ar) | المركبات المحتوية على البورون العطري ونظائر الأنسولين ذات الصلة | |
| MX2007003119A (es) | Nuevas amidas heterociclicas. |